Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

被引：6

作者：

Gurbuz, Mustafa ^{[1
]}

Kutlu, Yasin ^{[2
]}

Akkus, Erman ^{[3
]}

Koksoy, Elif Berna ^{[1
]}

Kose, Naziyet ^{[4
]}

Oven, Bala Basak ^{[5
]}

Uluc, Basak Oyan ^{[6
]}

Demiray, Atike Gokcen ^{[7
]}

Erdem, Dilek ^{[8
]}

Demir, Bilgin ^{[9
]}

Turhal, Nazim Serdar ^{[10
]}

Uskent, Necdet ^{[10
]}

Akbas, Sinem ^{[11
]}

Selcukbiricik, Fatih ^{[11
]}

Inal, Ali ^{[12
]}

Bilici, Ahmet ^{[2
]}

Olmez, Omer Fatih ^{[2
]}

Cabuk, Devrim ^{[13
]}

Unal, Caglar ^{[14
]}

Hizal, Mutlu ^{[15
]}

Sendur, Mehmet Ali Nahit ^{[15
]}

Korkmaz, Mustafa ^{[16
]}

Karadurmus, Nuri ^{[17
]}

Erturk, Ismail ^{[17
]}

Goksu, Sema Sezgin ^{[18
]}

Tatli, Ali Murat ^{[18
]}

Guven, Deniz Can ^{[19
]}

Kilickap, Saadettin ^{[20
]}

Paksoy, Nail ^{[21
]}

Aydiner, Adnan ^{[21
]}

Cinkir, Havva Yesil ^{[22
]}

Ozkul, Ozlem ^{[23
]}

Ozturk, Akin ^{[24
]}

Balli, Sevinc ^{[1
]}

Kemal, Yasemin ^{[8
]}

Erdogan, Atike Pinar ^{[25
]}

Er, Ozlem ^{[26
]}

Yumuk, Perran Fulden ^{[11
]}

Demirkazik, Ahmet ^{[1
]}

机构：

[1] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[2] Istanbul Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[3] Ankara Univ, Fac Med, Dept Internal Med, Ankara, Turkey

[4] Mem Ankara Hosp, Dept Med Oncol, Ankara, Turkey

[5] Bahcesehir Univ, Fac Med, Dept Med Oncol, Gortepe Med Pk Hosp, Istanbul, Turkey

[6] Acibadem Altunizade Hosp, Dept Med Oncol, Istanbul, Turkey

[7] Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkey

[8] Samsun Med Pk Hosp, Dept Med Oncol, Samsun, Turkey

[9] Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkey

[10] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkey

[11] Koc Univ Hosp, Dept Med Oncol, Istanbul, Turkey

[12] Mersin City Hosp, Dept Med Oncol, Mersin, Turkey

[13] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkey

[14] Gayrettepe Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkey

[15] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[16] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkey

[17] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey

[18] Akdeniz Univ, Fac Med, Dept Med Oncol, Antalya, Turkey

[19] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[20] Istinye Univ, Liv Ankara Hosp, Fac Med, Dept Med Oncol, Ankara, Turkey

[21] Istanbul Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[22] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey

[23] Bagcilar Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey

[24] Sureyyapasa Chest Dis & Thorac Surg Training & Re, Dept Med Oncol, Istanbul, Turkey

[25] Manisa Celal Bayar Univ, Dept Med Oncol, Fac Med, Manisa, Turkey

[26] Maslak Acibadem Hosp, Dept Med Oncol, Istanbul, Turkey

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2022年 / 148卷 / 12期

关键词：

Atezolizumab; Small cell lung cancer; Immunotherapy; PD-L1; ETOPOSIDE; PLATINUM;

D O I：

10.1007/s00432-022-04087-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.

引用

页码：3547 / 3555

页数：9

共 50 条

[31] Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
Zhu, Youwen
Liu, Kun
Qin, Qun
Zhu, Hong
FRONTIERS IN IMMUNOLOGY, 2023, 13
[32] Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Liao, Y. -T.
Sun, R. -L.
Huang, H. -C. H.
Shen, C. -I.
Tseng, Y. -H.
Luo, Y. -H.
Chen, Y. -M.
Chiang, C. -L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S676 - S676
[33] Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer - a meta-analysis
Chen, Ching-Yi
Chen, Wang-Chun
Hung, Chao-Ming
Wei, Yu-Feng
IMMUNOTHERAPY, 2021, 13 (14) : 1165 - 1178
[34] Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer
West, W
Birch, R
Schnell, F
Hainsworth, J
Tongol, J
Campos, L
ONCOLOGIST, 2003, 8 (01): : 76 - 82
[35] Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy
Zhang, Tiantian
Tao, Lu
Chen, Yufo
Zhang, Shanshan
Liu, Yang
Li, Yumei
Wang, Rui
CLINICAL RESPIRATORY JOURNAL, 2024, 18 (08):
[36] First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
Long, Rong
Chen, Fangping
SCIENTIFIC REPORTS, 2024, 14 (01):
[37] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
Daniel, D.
Kuchava, V.
Bondarenko, I.
Ivashchuk, O.
Spigel, D.
Dasgupta, A.
Reddy, S.
Melkadze, T.
Jaal, J.
Kudaba, I.
Hart, L.
Matitashvili, A.
Koynov, K. D.
Yang, Z.
Wolfe, S. G.
Malik, R.
Morris, S. R.
Antal, J. M.
Goldschmidt, J.
ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
[38] Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta -analysis
Wang, Shuxing
Li, Yunshu
Liu, Zhuqing
Tian, Wentao
Zeng, Yue
Liu, Junqi
Zhang, Sujuan
Peng, Yurong
Wu, Fang
LUNG CANCER, 2023, 178 : 47 - 56
[39] The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
Zheng, Hao-Ran
Jiang, Ai-Min
Gao, Huan
Liu, Na
Zheng, Xiao-Qiang
Fu, Xiao
Ruan, Zhi-Ping
Tian, Tao
Liang, Xuan
Yao, Yu
FRONTIERS IN ONCOLOGY, 2022, 12
[40] Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
Zhao, Ke
Lu, Shuangqing
Niu, Jiling
Zhu, Hui
Tian, Yaru
Yu, Jinming
BMC CANCER, 2025, 25 (01)

← 1 2 3 4 5 →